{"id":172213,"date":"2025-11-07T07:15:56","date_gmt":"2025-11-07T12:15:56","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172213"},"modified":"2025-11-07T07:15:56","modified_gmt":"2025-11-07T12:15:56","slug":"lupin-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/lupin-q2-fy26-earnings-results\/","title":{"rendered":"Lupin Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.<\/p>\n<p>&nbsp;<\/p>\n<h2 class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Q2 FY26 Earnings Results:<\/h2>\n<ul>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Revenue from Operations: \u20b97,047.51 crore, up 24.2% YoY and 12.4% QoQ from \u20b96,268 crore in Q1 FY26.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">EBITDA: \u20b92,137.6 crore, EBITDA margin 31.3% (up 750 bps YoY).<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Profit After Tax (PAT): \u20b91,485 crore, up 73% YoY from \u20b9852.6 crore in Q2 FY25.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">PAT margin: Approx. 21%.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">North America segment: Grew 46% YoY to \u20b92,762 crore (USD 315 million).<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">India: Continued strong performance contributing 35% of revenue.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Emerging markets sales: \u20b9922.8 crore, up 45.3% YoY, around 14% of global revenue.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Gross profit: \u20b95,006.6 crore, gross margin 73.3%.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Personnel costs: \u20b91,105.6 crore, 16.2% of sales.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Manufacturing and other expenses: \u20b91,979.6 crore (29% of sales).<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Employee count: Not specifically stated for Q2 FY26.<\/li>\n<\/ul>\n<h3><\/h3>\n<h3 class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Management Commentary &amp; Strategic Decisions<\/h3>\n<ul>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Managing Director Nilesh Gupta stated this was &#8220;<a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/c325e5e2-fc10-4bc7-aa62-d453622ffb60.pdf\" target=\"_blank\" rel=\"noopener\">one of our strongest performances ever<\/a>,&#8221; highlighting robust growth across the U.S., emerging markets, other developed markets, and India.<br \/>\nStrong operational efficiencies and sustained investments supported the margin expansion.<br \/>\nStrategic moves included new product launches like Liraglutide and Risperidone injections in the U.S.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Global expansion was boosted by VISUfarma acquisition (ophthalmology) and an out-licensing partnership with Sandoz for Ranibizumab biosimilar.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Regulatory approvals were received in Taiwan, Brazil, and Mexico.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Ongoing focus on R&amp;D with investment of \u20b9509.1 crore during the quarter to support pipeline and capacity expansion.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">The company aims to leverage the first-half momentum for a strong full-year FY26.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-172215\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results-839x1024.png\" alt=\"Lupin Q2 FY26 Earnings Results\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Q1 FY26 Earnings Results:<\/h2>\n<ul>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Revenue from Operations: \u20b96,268.34 crore, up 11.9% YoY from \u20b95,600.33 crore in Q1 FY25.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">EBITDA: Around \u20b91,329 crore (calculated from EBITDA margin 20.9%).<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Profit After Tax (PAT): \u20b91,219.03 crore, up 52.13% YoY from \u20b9801.31 crore.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">North America sales: \u20b92,404.1 crore, up 24.3% YoY, 39% of total revenue.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">India sales: \u20b92,089.4 crore, up 7.8% YoY, 34% of total revenue.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Other developed markets: \u20b9774.8 crore, up 17.4% YoY, 13% of revenue.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Emerging markets: \u20b9652.4 crore, up 5.2% YoY.<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">R&amp;D expenses: \u20b9356 crore (6.9% of sales).<\/li>\n<li class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Management highlighted sustained market demand, stable U.S. generics portfolio, and Indian business growth, with focus on inhalation, injectables, biosimilars, and complex generics.<\/li>\n<\/ul>\n<p>To view the company\u2019s previous earnings and latest concall transcripts,\u00a0<a href=\"https:\/\/44.250.171.167\/symbol\/lupin\/\">click here<\/a>\u00a0 to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. &nbsp; Q2 FY26 Earnings Results: [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":172215,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[10162],"class_list":["post-172213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lupin-Q2-FY26-Earnings-Results.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":169792,"url":"https:\/\/alphastreet.com\/india\/lupin-ltd-q1-fy26-earnings-results-51-rise-in-profits\/","url_meta":{"origin":172213,"position":0},"title":"Lupin Ltd Q1 FY26 Earnings Results &#8211; 51% rise in Profits","author":"Chirag Gupta","date":"August 6, 2025","format":false,"excerpt":"Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lupin Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/1-4.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172155,"url":"https:\/\/alphastreet.com\/india\/sun-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172213,"position":1},"title":"Sun Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 5, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172440,"url":"https:\/\/alphastreet.com\/india\/torrent-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172213,"position":2},"title":"Torrent Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 17, 2025","format":false,"excerpt":"Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. \u00a0 Q2 FY26 Earnings Results: Revenue from Operations: \u20b93,302 crore, up 14% YoY from \u20b92,889 crore EBITDA: \u20b91,083 crore, up 15.3% YoY; EBITDA margin expanded to 32.8% (from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Torrent Pharmaceuticals Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Torrent-Pharmaceuticals-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177358,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","url_meta":{"origin":172213,"position":3},"title":"Laurus Labs Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 23, 2026","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171740,"url":"https:\/\/alphastreet.com\/india\/rpg-life-sciences-q2-fy26-earnings-results\/","url_meta":{"origin":172213,"position":4},"title":"RPG Life Sciences Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"October 22, 2025","format":false,"excerpt":"Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients. Presenting below are its Q2 FY26 earnings results. \u00a0 Q2 FY26 Earnings Results Revenue from Operations:\u00a0\u20b9181.7 crore, up\u00a05.5% YoY\u00a0from \u20b9172.2 crore and\u00a07.6% QoQ\u00a0from \u20b9168.9 crore in Q1 FY26, driven by strong domestic\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"RPG Life Sciences Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172355,"url":"https:\/\/alphastreet.com\/india\/orchid-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172213,"position":5},"title":"Orchid Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 12, 2025","format":false,"excerpt":"Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b9193.52 crore, down 13.1% YoY but up 11.9% QoQ EBITDA: \u20b9-1.48 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Orchid Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Orchid-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172213"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172213\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172215"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}